<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809831</url>
  </required_header>
  <id_info>
    <org_study_id>2021-PERIBIOMA</org_study_id>
    <nct_id>NCT04809831</nct_id>
  </id_info>
  <brief_title>The Use of Biorepair Peribioma Toothpaste and Mousse for Home Oral Care in Patients Undergoing Periodontal Therapy</brief_title>
  <official_title>A Comparison Between Biorepair Peribioma Toothpaste and Mousse Versus Chlorhexidine 0,2% Toothpaste (Curasept Trattamento Rigenerante) for Domiciliary Oral Care in Periodontal Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label split-mouth randomized clinical trial in which a new domiciliary oral&#xD;
      care protocol with Biorepair Peribioma Toothpaste and Mousse is evaluated in periodontal&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label split-mouth randomized clinical trial that aims to suggest an&#xD;
      innovative protocol for domiciliary oral care of periodontal patients. In details, home use&#xD;
      of Biorepair Peribioma Toothpaste and Mousse is proposed as a support of professional hygiene&#xD;
      sessions.&#xD;
&#xD;
      Patients that respond to the eligibility criteria and that sign the informed consent are&#xD;
      recruited for periodontal therapy.The first professional hygiene session is performed at the&#xD;
      baseline (T0); the following ones will be performed after 3 (T1) and 6 months (T2) from the&#xD;
      baseline. In each session, periodontal indices of inflammation are detected; then,&#xD;
      subgingival removal of plaque and tartar is performed, followed by glycine/erythritol&#xD;
      air-flow application in periodontal pockets. A microbiological test is perfomed in order to&#xD;
      detect red and orange complex bacteria. At this time, patients are randomly allocated into&#xD;
      two groups:&#xD;
&#xD;
        -  Trial Group: domiciliary oral hygiene with Biorepair Peribioma Toothpaste and Mousse&#xD;
           twice a day until T2 session.&#xD;
&#xD;
        -  Control Group: home oral hygiene with Curasept Toothpaste (0,2% Chlorhexidine) twice a&#xD;
           day until T2 session.&#xD;
&#xD;
      At the end of T1 and T2 professional session, a satisfaction survey about Peribioma&#xD;
      Toothpaste and Mousse will ben given to the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Actual">November 3, 2021</completion_date>
  <primary_completion_date type="Actual">October 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open-label study in which patients are divided into two groups:&#xD;
Trial Group: professional dental hygiene at T0, T1 and T2 + Biorepair Peribioma Toothpaste and Mousse for domiciliary oral care twice a day until T2;&#xD;
Control Group: professional dental hygiene at T0, T1 and T2 + Curasept Toothpaste with chlorhexidine 0,2% twice a day until T2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BOP - Bleeding on Probing (percentage)</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Site-specific assessment of the presence or absence of gum bleeding after the insertion of the periodontal probe for the detection of PPD, detected on 6 sites.&#xD;
Percentage of sites with bleeding on probing determines the BOP%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in BS - Bleeding Score</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Scoring criteria:&#xD;
0 = no bleeding;&#xD;
1 = punctiform bleeding in the site of probing;&#xD;
2 = slightly extended bleeding in the site of probing;&#xD;
3 = bleeding in more than a half of gingival margin;&#xD;
4 = gingival border fully covered by blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SBI - Sulculus Bleeding Index (Muhulemann and Son, 1781)</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Scoring criteria:&#xD;
0 = healthy looking papillary and marginal gingiva, no bleeding on probing;&#xD;
1 = healthy looking gingiva, with bleeding on probing;&#xD;
2 = bleeding on probing, change in color, no edema;&#xD;
3 = bleeding on probing, change in color, slight edema;&#xD;
4 = bleeding on probing, change in color, obvious edema;&#xD;
5 = spontaneous bleeding, change in color, marked edema.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in GI - Gingival Index (Loe and Silness, 1963)</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Scoring criteria:&#xD;
0 = normal gingiva.&#xD;
1 = mild inflammation, edema and swelling; no bleeding.&#xD;
2 = moderate inflammation with edema, swelling and bleeding on probing.&#xD;
3 = severe inflammation with marked edema, redness tissues, ulceration and spontaneous bleeding.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PPD - Probing Pocket Depth</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Evaluation (in mm) of the depth of the gingival sulcus, through a millimeter periodontal probe; it is detected from the gingival margin to the bottom of the gingival sulcus or periodontal pocket, evaluated at 6 sites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CAL - Clinical Attachment Loss</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Measurement (in mm) of the position of the gingival margin in relation to the cemento-enamel junction (CEJ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of pathological sites</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Evaluation of the presence of pathological probes expressed as a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in R - Gingival recession</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Distance (in mm) between the gingival margin and the amelo-cemental junction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PI - Plaque Index (Silness and LÃ¶e, 1964)</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Scoring criteria:&#xD;
0 = no plaque;&#xD;
1 = thin plaque layer at the gingival margin, only detectable by scraping with a probe;&#xD;
2 = moderate layer of plaque along the gingival margin; interdental spaces free, but plaque is visible to the naked eye;&#xD;
3 = abundant plaque along the gingival margin; interdental spaces filled with plaque.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Evaluation of the total height of the adherent gingiva</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Evaluation (in mm) of the total height of adherent gingiva.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in API - Approximal Plaque Index (Lange, 1986)</measure>
    <time_frame>3 and 6 months.</time_frame>
    <description>Following application of disclosing, a simple yes/no decision is made concerning whether the interproximal surfaces are covered by plaque (+) or not (-). The proportion of plaque-covered interproximal spaces is expressed as a percentage. Usually, in a given quadrant the interproximal spaces are scored from only one aspect (i.e. from the facial - Q2 and Q4 - or from the oral aspect - Q1 and Q3).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Periodontal Diseases</condition>
  <arm_group>
    <arm_group_label>Trial Group - Biorepair Peribioma Toothpaste + Mousse</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Domiciliary oral hygiene with Biorepair Peribioma Toothpaste in association with Peribioma Mousse twice a day until T2 session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group - Curasept Toothpaste (chlorhexidine 0,2%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%) twice a day until T2 session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse</intervention_name>
    <description>Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.</description>
    <arm_group_label>Trial Group - Biorepair Peribioma Toothpaste + Mousse</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)</intervention_name>
    <description>Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.</description>
    <arm_group_label>Control Group - Curasept Toothpaste (chlorhexidine 0,2%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of periodontal disease according to the recent 2017 classification (2017&#xD;
             World Workshop on the Classification of Periodontal and Peri-Implant Diseases and&#xD;
             Conditions): severity grade II-III and complexity grade I-II.&#xD;
&#xD;
          -  Presence of bilateral periodontal probes, for at least one tooth per side up to 20&#xD;
             elements with pathologic probes).&#xD;
&#xD;
          -  Patients' good compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cardiac pacemaker&#xD;
&#xD;
          -  Patients suffering from neurological disorders&#xD;
&#xD;
          -  Patients suffering from psychological disorders&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Scribante, DDS, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit of Dental Hygiene - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia</name>
      <address>
        <city>Pavia</city>
        <state>Lombardy</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Andrea Scribante</investigator_full_name>
    <investigator_title>Research Resident, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>dental hygiene</keyword>
  <keyword>periodontal non-surgical therapy</keyword>
  <keyword>split-mouth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be available upon motivated request to Principal Investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

